Axsome Therapeutics Shares Decline Amid Record Revenue and Pipeline Progress

Axsome Therapeutics reports strong 2025 revenue growth led by Auvelity and advances Phase 3 depression trial, but shares fall as investors focus on net losses.

Axsome Therapeutics, a biopharmaceutical company, reported significant revenue growth and advanced a key clinical study this week. However, its shares experienced a notable sell-off, highlighting investor caution despite the positive developments.

Financial Performance Shows Strong Traction

Earlier this week, Axsome released financial results for the fourth quarter and full year 2025. The company's product revenue surged to $196.0 million in Q4, representing a substantial 65% increase year-over-year. For the complete fiscal year 2025, total revenue reached $638.5 million, climbing 66%.

The primary growth engine was the depression treatment Auvelity. It generated $155.1 million in the final quarter alone, a 68% jump, stemming from approximately 225,000 prescriptions. The sleep disorder therapy Sunosi also contributed, with sales of $36.7 million marking a 40% rise.

Despite this robust commercial performance, Axsome has not yet reached profitability. The net loss for Q4 2025 was $28.6 million, or $0.56 per share. The annual net loss totaled $183.2 million. The company ended the year with a solid cash position, holding $322.9 million in liquid assets.

Clinical Pipeline Advances with Key Study

In a separate development, Axsome announced the dosing of the first patient in its Phase 3 CLARITY trial. This study is evaluating solriamfetol for the treatment of major depressive disorder (MDD) accompanied by excessive daytime sleepiness.

The condition represents a significant unmet medical need in the United States, where over 21 million adults suffer from depression. An estimated half of these individuals experience comorbid excessive sleepiness, for which there are currently no approved pharmaceutical treatments.

The CLARITY trial is designed as a randomized withdrawal study. Participants who initially respond to solriamfetol will later be randomly assigned to either continue the drug or switch to a placebo. The primary goal is to measure the time until a relapse of depressive symptoms occurs. Solriamfetol functions as a dopamine and norepinephrine reuptake inhibitor.

Market Response and Upcoming Catalyst

Investors appeared to weigh the clinical progress and strong financials against the ongoing losses, leading to a negative market reaction. The company's stock closed yesterday's session at $169.95, down approximately 4.88%. Trading volume was notably high, exceeding the 20-day average by more than 50%.

Attention now turns to a near-term regulatory catalyst that could influence the stock's trajectory. The U.S. Food and Drug Administration (FDA) is set to decide on a potential label expansion for Auvelity by April 30, 2026. The application seeks approval for treating agitation in patients with Alzheimer's disease.